Abstract:
INTRODUCTION:Moderate-to-severe AD burdens a large proportion of AD patients and may represent an inadequacy of treatment options available for resistant disease. AREAS COVERED:This review provides an overview of the therapies for moderate-to-severe AD in late-stage development and in the clinic, and focuses on baricitinib as an emerging therapeutic option. Baricitinib is an orally available selective JAK1/JAK2 inhibitor that is approved for use in the treatment of moderate-to-severe rheumatoid arthritis (RA). Baricitinib decreases AD lesions, disease severity, and improves quality of life. Overall, the small molecule inhibitor is well tolerated. However, its black-box warnings in the RA population raise a concern for its long-term safety. EXPERT OPINION:Baricitinib is a promising treatment modality for moderate-to-severe AD. Its primary advantage over dupilumab, the revolutionary biologic agent approved for AD, is that patients prefer an oral medication over an injection. However, providers will likely prescribe an injectable over an oral medication if baricitinib has an unfavorable safety profile. Insurance coverage of baricitinib will also have a major role in clinical use. Baricitinib will likely face competition from other JAK inhibitors in the future; however, it will have an advantage if it becomes the first FDA-approved medication of its kind for resistant AD.
journal_name
Expert Opin Pharmacotherjournal_title
Expert opinion on pharmacotherapyauthors
Mendes JT,Balogh EA,Strowd LC,Feldman SRdoi
10.1080/14656566.2020.1739268subject
Has Abstractpub_date
2020-06-01 00:00:00pages
1027-1033issue
9eissn
1465-6566issn
1744-7666journal_volume
21pub_type
杂志文章,多中心研究,评审abstract::Everolimus is a novel immunosuppressive agent related to sirolimus. It is a proliferation signal inhibitor with an improved pharmacokinetic profile and bioavailability compared with sirolimus. Everolimus has been shown to be as effective as mycophenolate mofetil in reducing acute rejection in renal transplantation. In...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.7.10.1347
更新日期:2006-07-01 00:00:00
abstract:INTRODUCTION:Sorafenib is a novel oral bis-aryl urea compound that has proven survival benefit in patients with advanced hepatocellular carcinoma (HCC), for which several therapies are currently available with unsatisfactory results. Sorafenib is the first compound to demonstrate a significant effect on survival in HCC...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2011.546346
更新日期:2011-02-01 00:00:00
abstract::Diabetes mellitus has reached epidemic proportions in many countries and is the most common cause of end stage renal disease (ESRD). The angiotensin II receptor-1 (AT(1)) antagonists losartan and irbesartan have recently been evaluated as renoprotective agents in large clinical trials of patients with Type 2 diabetes ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1517/14656566.3.5.625
更新日期:2002-05-01 00:00:00
abstract:INTRODUCTION:Irritable bowel syndrome (IBS) treatment is challenging physicians because of its multifactorial physiopathology. In particular, abdominal pain and diarrhea management lack one unique effective pharmacological remedy. Opioid receptors, present in the central nervous system (CNS) and the enteric nervous sys...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2016.1182982
更新日期:2016-07-01 00:00:00
abstract:OBJECTIVE:In a previous multicentre study including 129 HIV-infected children, non-adherence to antiretroviral therapy was detected in 16% of patients and was mainly related to psychosocial rather than clinical or demographic features. The aim of this study was to explore the evolving pattern of adherence and its deter...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,多中心研究
doi:10.1517/14656560903376178
更新日期:2009-12-01 00:00:00
abstract:INTRODUCTION:Advances in acute lymphocytic leukemia (ALL) therapy has led to long-term survival rates in children. However, only 30%-40% of adults achieve long-term disease-free survival. After relapse, the outcome of salvage chemotherapy is very disappointing with less than 10% of long survival. Novel agents are there...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2016.1250884
更新日期:2016-12-01 00:00:00
abstract::Management of patients undergoing cardiac surgery has evolved in recent years as more is understood about the physiological changes and responses that occur during and after cardiopulmonary bypass (CPB). In particular, our understanding of the mechanisms involved in haemostasis and in the inflammatory response to bypa...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.1.7.1353
更新日期:2000-12-01 00:00:00
abstract:INTRODUCTION:Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from stu...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2014.889116
更新日期:2014-04-01 00:00:00
abstract:INTRODUCTION:Rheumatoid arthritis (RA) can spontaneously improve during pregnancy. However, a considerable proportion of patients can experience a flare and high disease activity has been associated with an increased risk of adverse pregnancy outcome. Thus, the treatment of RA in pregnant women should be selected takin...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2016.1197204
更新日期:2016-08-01 00:00:00
abstract:INTRODUCTION:Treating acute myeloid leukemia (AML) in older adults remains daunting. The unique biology often renders conventional chemotherapies less effective. Accurately predicting the toxicities of treatment is another unresolved challenge. Treatment planning thus requires a good knowledge of the current trial data...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2018.1465562
更新日期:2018-06-01 00:00:00
abstract:INTRODUCTION:Ziconotide is an N-type calcium channel antagonist to treat chronic pain that is delivered intrathecally. It is the only intrathecal, FDA-approved, non-opioid analgesic and is recommended as first-line therapy. Despite these advantages, a small therapeutic window limits ziconotide's clinical utility, with ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2013.784269
更新日期:2013-05-01 00:00:00
abstract:BACKGROUND:The management of thyroid cancer is difficult because the tumors comprise a wide range of biologic behaviors, from small papillary thyroid microcarcinomas that pose little or no threat to survival for the patient, to anaplastic thyroid cancers that are arguably the most lethal tumor. Although it may be diffi...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.9.15.2627
更新日期:2008-10-01 00:00:00
abstract:INTRODUCTION:Lacosamide is a novel antiepileptic drug licensed in the US and Europe as adjunctive therapy for partial-onset seizures in adults. The efficacy, safety, tolerability and favorable pharmacokinetic profile in the adult population suggest that lacosamide could be of benefit for patients with partial-onset sei...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2012.713347
更新日期:2012-10-01 00:00:00
abstract::Recognising the value added by economic evaluations of clinical trials and the interaction of clinical, humanistic and economic end points, the Radiation Therapy Oncology Group (RTOG) has developed an Outcomes Model that guides the comprehensive assessment of this triad of end points. This paper will focus on the econ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.5.3.513
更新日期:2004-03-01 00:00:00
abstract::Diabetes mellitus is now occurring in epidemic proportions in many countries. Owing to the limited effectiveness of drug prophylaxis of diabetic complications after diabetes has developed, it may be more appropriate to investigate ways to prevent the onset of diabetes. A recent trial published by the Diabetes Preventi...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1517/14656566.3.7.1011
更新日期:2002-07-01 00:00:00
abstract:INTRODUCTION:Hyperphosphatemia in chronic kidney disease (CKD) is considered as an independent risk factor for surrogate clinical end points like vascular calcification (VC) and bone disease, or hard clinical outcomes like cardiovascular events. Various treatment options are available for phosphate removal or reduction...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2015.1092521
更新日期:2015-01-01 00:00:00
abstract::Poor therapeutic adherence is a major issue faced by physicians today. This paper summarizes the adherence rates with oral bisphosphonate (OBP) treatment in clinical practice and their impact on clinical outcomes. Studies systematically demonstrated that overall compliance and persistence with OBPs among osteoporotic ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656560903140533
更新日期:2009-10-01 00:00:00
abstract::In the recent years, advances in the treatment of chronic hepatitis B and C have shown that newer, more expensive therapy may result in higher sustained viral response rates. In light of this, the pertinent question for healthcare decision-makers centres around whether this increase in efficacy 'justifies' the additio...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2.2.205
更新日期:2001-02-01 00:00:00
abstract::Desvenlafaxine (DESV) is a newer antidepressant, which inhibits serotonin-norepinephrine reuptake neurotransmission, similarly to venlafaxine, milnacipran and duloxetine. It was approved in February 2008 by the FDA for the treatment of major depressive disorder (MDD), based on well-controlled and adequately powered, l...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2011.636033
更新日期:2011-12-01 00:00:00
abstract::Cough-variant asthma is considered as an asthma subset in which chronic cough is the only symptom. It is believed to be more frequent and, hence, sometimes overdiagnosed in children, and shares with typical asthma eosinophilic airway inflammation and consequent bronchial hyper-responsiveness. Presently available thera...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.8.17.3021
更新日期:2007-12-01 00:00:00
abstract:INTRODUCTION:Despite the availability of numerous anti-diabetes drugs and treatment guidelines, many patients with type 2 diabetes mellitus (T2DM) do not reach recommended targets for glycemic control. There remains an unmet need for effective and well-tolerated anti-diabetes agents that can be used as monotherapy or i...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2014.966078
更新日期:2014-11-01 00:00:00
abstract:INTRODUCTION:Chronic pruritus is a common symptom that arises from both dermatologic and non-dermatologic conditions including chronic kidney disease, cholestasis, lymphoma and neuropathy. Over the past decade, research has elucidated many of the receptors, neuropeptides and cytokines involved in itch sensation and tra...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2016.1127355
更新日期:2016-01-01 00:00:00
abstract:INTRODUCTION:Pharmacotherapy with visual cycle modulators (VCMs) is under investigation for retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt macular dystrophy (SMD) and nonexudative age-related macular degeneration (AMD), all blinding diseases that lack effective treatment options. AREAS COVERED:...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2018.1448060
更新日期:2018-04-01 00:00:00
abstract:INTRODUCTION:Human respiratory syncytial virus (hRSV) is the primary viral cause of respiratory diseases, leading to bronchiolitis and pneumonia in vulnerable populations. The only current treatment against this virus is palliative, and no efficient and specific vaccine against this pathogen is available. AREAS COVERE...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2020.1806821
更新日期:2020-12-01 00:00:00
abstract:BACKGROUND:Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive breast cancer. OBJECTIVE:To determine whether the aromatase inhibitor anastrozole should replace tamoxifen as the adjuvant treatment in this cancer. METHODS:Two recent trials of anastrozole and tamoxifen as adju...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1517/14656566.9.9.1619
更新日期:2008-06-01 00:00:00
abstract:INTRODUCTION:Malaria in pregnancy continues to be a significant public health burden globally, with over 100 million women at risk each year. Sulfadoxine-pyrimethamine (SP) is the only antimalarial recommended for intermittent preventive therapy in pregnancy (IPTp) but increasing parasite resistance threatens its viabi...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2018.1526923
更新日期:2018-11-01 00:00:00
abstract:BACKGROUND:Skin and skin structure infections are frequently encountered in clinical practice. Fortunately, these infections usually produce only mild to moderate symptoms and signs. Some, however, are severe and may even be life-threatening. OBJECTIVE:To review the approach to the evaluation and treatment of patients...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.9.5.717
更新日期:2008-04-01 00:00:00
abstract::Synovitis is a painful and, occasionally, disabling disease. Patients with synovitis, especially new onset synovitis, should be referred to a rheumatologist urgently so that they can be assed and treated as quickly as possible. Clinical assessment and investigations are required to help differentiate between transient...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.7.1.35
更新日期:2006-01-01 00:00:00
abstract:INTRODUCTION:Treatment of unresectable or metastatic urothelial carcinoma (UC) has historically relied upon platinum-based chemotherapy and, more recently, immune checkpoint inhibitors. When tumors progress despite those therapies, remaining effective options are limited. AREAS COVERED:In this review, the authors revi...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2020.1736036
更新日期:2020-06-01 00:00:00
abstract:INTRODUCTION:Breast cancer (BC) remains the most frequently diagnosed cancer and the most common cause of cancer death among women of all races worldwide. Over 80% of BC cases are hormone receptor (HR)-positive, comprised of luminal A and luminal B per molecular subtypes, imposing an urgent need to fully understand the...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1080/14656566.2018.1429407
更新日期:2018-02-01 00:00:00